Patents by Inventor Andreas Weichert

Andreas Weichert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9014553
    Abstract: A satellite test signal reflection apparatus for testing transmitters sending out optical signals, the apparatus includes a plate that is at least partially permeable to optical signals. The plate has a base with a first surface with a residual reflective coating and a second surface. The residual reflective coating is configured to split an optical beam, which penetrates the plate in a first direction from the first surface to the second surface, into a reflective optical beam and a transmitted optical beam.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: April 21, 2015
    Assignee: Tesat-Spacecom GmbH & Co. KG
    Inventor: Andreas Weichert
  • Publication number: 20130343746
    Abstract: A satellite test signal reflection apparatus for testing transmitters sending out optical signals, the apparatus includes a plate that is at least partially permeable to optical signals. The plate has a base with a first surface with a residual reflective coating and a second surface. The residual reflective coating is configured to split an optical beam, which penetrates the plate in a first direction from the first surface to the second surface, into a reflective optical beam and a transmitted optical beam.
    Type: Application
    Filed: June 24, 2013
    Publication date: December 26, 2013
    Inventor: Andreas WEICHERT
  • Patent number: 7132536
    Abstract: The present invention relates to triaza- and tetraaza-anthracenedione derivatives of the formula I, wherein A, B and R1 to R5 are as defined herein. The compounds of formula I are valuable pharmacologically active compounds. They are useful in the treatment of various disease states including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency. They upregulate the expression of the enzyme endothelial nitric oxide (NO) synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: April 21, 2004
    Date of Patent: November 7, 2006
    Assignee: Sanofi-aventis Deutschland GmbH
    Inventors: Andreas Weichert, Hartmut Strobel, Paulus Wohlfart, Marcel Patek, Martin Smrcina, Aleksandra Weichsel
  • Publication number: 20060111353
    Abstract: According to the present invention there is provided a compounds of formula (I): and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: December 16, 2003
    Publication date: May 25, 2006
    Inventors: Andreas Weichert, David Barrett, Stefan Heuser, Rainer Riedl, Mark Tebbe, Andrea Zaliani
  • Publication number: 20040248900
    Abstract: The present invention relates to triaza- and tetraaza-anthracenedione derivatives of the formula I, 1
    Type: Application
    Filed: April 21, 2004
    Publication date: December 9, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Andreas Weichert, Hartmut Strobel, Paulus Wohlfart, Marcel Patek, Martin Smrcina, Aleksandra Weichsel
  • Patent number: 6703411
    Abstract: Benzoylguanidines of the formula (I) in which R1 to R4 have the meanings given in the specification and claims are suitable as antiarrhythmic medicaments having a cardioprotective component for infarct prophylaxis and infarct treatment and for the treatment of angina pectoris. The compounds of the invention also preventively inhibit the pathophysiological processes in the formation of ischemically induced damage, in particular in the triggering of ischemically induced cardiac arrhythmias.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: March 9, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Andreas Weichert, Udo Albus, Hans-Willi Jansen, Heinz-Werner Kleemann, Hans Jochen Lang
  • Publication number: 20040044081
    Abstract: Diacyl-substituted guanidines, a process for their preparation, their use as medicament or diagnostic aid, and medicament containing them.
    Type: Application
    Filed: August 15, 2003
    Publication date: March 4, 2004
    Applicant: Hoechst Aktiengesellschaft
    Inventors: Heinz-Werner Kleemann, Hans-Jochen Lang, Andreas Weichert, Peter Crause, Wolfgang Scholz, Udo Albus, Jan-Robert Schwark
  • Patent number: 6632840
    Abstract: Monoacyl-substituted guanidines of formula III, or a salt or acid thereof, and their use as medicine or diagnostic aid: in which X(2) is
    Type: Grant
    Filed: March 24, 2000
    Date of Patent: October 14, 2003
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Heinz-Werner Kleemann, Hans-Jochen Lang, Andreas Weichert, Peter Crause, Wolfgang Scholz, Udo Albus, Jan-Robert Schwark
  • Patent number: 6617344
    Abstract: Heterocyclically substituted benzoylguanidines of the formula I in which the substituents R(1) to R(4) have the meanings indicated in the claims. These compounds I are suitable as antiarrhythmic pharmaceuticals having a cardioprotective component for infarct prophylaxis and infarct treatment, and also for the treatment of angina pectoris. They also preventively inhibit the pathophysiological processes in the formation of ischemically induced damage, in particular in the elicitation of ischemically induced cardiac arrhythmias.
    Type: Grant
    Filed: January 28, 2003
    Date of Patent: September 9, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Andreas Weichert, Udo Albus, Hans-Willi Jansen, Heinz-Werner Kleemann, Hans-Jochen Lang
  • Publication number: 20030139607
    Abstract: Heterocyclically substituted benzoylguanidines of the formula I 1
    Type: Application
    Filed: January 28, 2003
    Publication date: July 24, 2003
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Andreas Weichert, Udo Albus, Hans-Willi Jansen, Heinz-Werner Kleemann, Hans-Jochen Lang
  • Patent number: 6593352
    Abstract: Substituted anthranilic acids of the formula I their use as a medicament or diagnostic, and medicament comprising them, and a pharmaceutical combination preparation containing a sodium/hydrogen exchange (NHE) blocker.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: July 15, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Andreas Weichert, Hans-Willi Jansen, Heinz-Werner Kleemann, Hans-Jochen Lang, Hartmut Rütten
  • Patent number: 6573288
    Abstract: The invention relates to compounds of formula (I) in which the symbols have the meanings given in the claims. Said compounds are inhibitors of the sodium-dependent bicarbonate/chloride ion exchanger which can be used as medicines for the prophylaxis or treatment of a wide range of diseases, for example the treatment and/or prophylaxis of myocardial infarction, angina pectoris, diseases caused by ischaemia, impaired respiration, cardiac ischaemia, ischaemia of the peripheral and central nervous system and stroke, ischaemia of the peripheral organs and limbs and diseases in which cell proliferation is a primary or secondary cause, in the treatment of shock, during surgical interventions and organ transplants or for preserving and storing transplants to be used in surgical interventions.
    Type: Grant
    Filed: November 3, 2000
    Date of Patent: June 3, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Andreas Weichert, Hans Jochen Lang, Stefan Petry, Jan-Robert Schwark, Heinz-Werner Kleemann, Sabine Faber, Hans-Willi Jansen
  • Patent number: 6504057
    Abstract: This invention relates to fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them. An embodiment of the invention embraces compounds of the formula I: and the pharmaceutically tolerated salts thereof. The disclosed compounds are valuable inhibitors of the cellular sodium/proton exchanger (Na+ /H+ exchanger) . They are therefore outstandingly suitable for the treatment of all diseases attributable to increased Na+ /H+ exchange.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: January 7, 2003
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Jan-Robert Schwark, Hans-Jochen Lang, Heinz-Werner Kleemann, Andreas Weichert, Wolfgang Scholz, Udo Albus
  • Patent number: 6486189
    Abstract: Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them. Compounds of the formula I in which the symbols have the meanings indicated in the claims, have outstanding antiarrhythmic properties and exhibit a cardioprotective component. They can preventively inhibit or greatly decrease the pathophysiological processes in the formation of ischemically induced damage, in particular in the elicitation of ischemically induced cardiac arrhythmias. Moreover, they have a potent inhibitory action on the proliferation of cells.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: November 26, 2002
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Heinz-Werner Kleemann, Hans Jochen Lang, Jan-Robert Schwark, Andreas Weichert, Sabine Faber, Hans-Willi Jansen
  • Publication number: 20020123529
    Abstract: This invention relates to fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them.
    Type: Application
    Filed: December 20, 2001
    Publication date: September 5, 2002
    Applicant: Hoechst Aktiengesellschaft
    Inventors: Jan-Robert Schwark, Hans-Jochen Lang, Heinz-Werner Kleemann, Andreas Weichert, Wolfgang Scholz, Udo Albus
  • Publication number: 20020123632
    Abstract: Substituted anthranilic acids of the formula I 1
    Type: Application
    Filed: December 6, 2001
    Publication date: September 5, 2002
    Inventors: Andreas Weichert, Hans-Willi Jansen, Heinz-Werner Kleemann, Hans-Jochen Lang, Hartmut Rutten
  • Patent number: 6436999
    Abstract: Diacyl-substituted guanidines of the formula I are described where X(1) and X(2) are as defined herein. The compounds are suitable for use as antiarrhythmic pharmaceuticals possessing a cardioprotective component for the prophylaxis and treatment of infarction and for the treatment of angina pectoris, in connection with which they also inhibit or strongly reduce, in a preventitive manner the pathophysiological processes associated with the genesis of ischemically induced damage, in particular associated with the elicitation of ischemically induced cardiac arrhythmias.
    Type: Grant
    Filed: April 18, 1997
    Date of Patent: August 20, 2002
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Heinz-Werner Kleemann, Hans-Jochen Lang, Andreas Weichert, Peter Crause, Wolfgang Scholz, Udo Albus, Jan-Robert Schwark
  • Publication number: 20020099222
    Abstract: Heterocyclically substituted benzoylguanidines of the formula I 1
    Type: Application
    Filed: February 15, 2002
    Publication date: July 25, 2002
    Inventors: Andreas Weichert, Udo Albus, Hans-Willi Jansen, Heinz-Werner Kleemann, Hans-Jochen Lang
  • Publication number: 20020045761
    Abstract: Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them.
    Type: Application
    Filed: October 30, 2001
    Publication date: April 18, 2002
    Inventors: Heinz-Werner Kleemann, Hans Jochen Lang, Jan-Robert Schwark, Andreas Weichert, Sabine Faber, Hans-Willi Jansen
  • Patent number: 6372917
    Abstract: The invention relates to compounds of formula (I), wherein the symbols have the meanings indicated in the specification. The inventive compounds exhibit dramatic antiarrhythmic proprieties and contain a cardioprotective compound. They can preventively inhibit or strongly reduce pathophysiologic processes upon occurrence of ischemic injuries, especially ischemic cardiac arrhythmia. Said compounds also exhibit a strong inhibiting effect on cellular proliferation.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: April 16, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Heinz-Werner Kleemann, Hans Jochen Lang, Jan-Robert Schwark, Andreas Weichert, Stefan Petry